John Berry Haycraft
1857-1922 · British (Scottish) · Biochemistry
Edinburgh physiologist who discovered hirudin in 1884, founding the modern molecular pharmacology of leech saliva.
Profile
- Life years
- 1857-1922
- Nationality
- British (Scottish)
- Era
- 19th century
- Primary field
- Biochemistry
Institutional Affiliations
- University of Edinburgh Medical School
- University College Cardiff (Department of Physiology, Chair 1893-1922)
- Royal Society of London (Fellow)
Key Contributions
- Isolated the anticoagulant principle from Hirudo medicinalis salivary glands in 1884 and named it 'hirudin' — the first identified leech bioactive compound.
- Demonstrated that hirudin blocks blood coagulation in vitro through a direct enzymatic interaction, decades before thrombin was characterized.
- Established Edinburgh's University Physiological Laboratory as the cradle of leech pharmacology research.
- Published the foundational 1884 paper 'On the Action of a Secretion Obtained from the Medicinal Leech on the Coagulation of the Blood,' cited by every hirudin paper since.
- Trained a generation of British physiologists who continued anticoagulant research into the 20th century.
Importance to Hirudotherapy
John Berry Haycraft's 1884 isolation of hirudin from medicinal leech salivary glands is the single most important event in the molecular history of hirudotherapy. Before Haycraft, the leech was a folk-medicine instrument whose action was attributed to vague 'humoral' or mechanical effects. By demonstrating that a specific chemical secretion was responsible for the prolonged bleeding observed after a leech bite — and that this secretion could be extracted, concentrated, and applied to blood in vitro — Haycraft transformed hirudotherapy from empirical practice into experimental pharmacology. His methodological choice mattered as much as his discovery. Haycraft used Edinburgh's then-novel saline-perfusion technique to flush the leech's anterior salivary glands, then tested the extract against fibrinogen-rich plasma. The resulting non-clotting phenomenon was reproducible, dose-dependent, and species-specific. He correctly inferred (without understanding thrombin) that the active principle interfered with the final step of fibrin formation. Modern crystallographic work — Stone & Hofsteenge in 1986, the PDB structures 1HRT and 4HTC — confirmed Haycraft's intuition with atomic precision: hirudin binds thrombin's active and exosite-1 surfaces with sub-picomolar affinity. Hirudin seeded an entire anticoagulant drug class. Two recombinant hirudin analogs reached the clinic — desirudin (FDA-approved, marketed) and lepirudin (approved 1998, voluntarily withdrawn in 2012) — and the rationally designed synthetic peptide bivalirudin (marketed) was built directly on hirudin's bivalent thrombin-binding architecture. Later synthetic small-molecule inhibitors such as dabigatran were inspired by the same thrombin-inhibition principle Haycraft uncovered, not derived from hirudin itself. The American Society of Hirudotherapy considers him the patron of evidence-based leech medicine — a 19th-century scientist whose careful protocols made it impossible for later generations to dismiss leech therapy as superstition.
Key Publications
- On the Action of a Secretion Obtained from the Medicinal Leech on the Coagulation of the Blood · Proceedings of the Royal Society of London (1884)
- Über die Einwirkung eines Sekretes des officinellen Blutegels auf die Blutgerinnung · Archiv für Experimentelle Pathologie und Pharmakologie (1884)
- On the Objection to Pain (Smithsonian Lecture) · Nature (1895)
Notable Quotes
“In conclusion, then, it may be stated that the leech secretes from its mouth a fluid which destroys the blood ferment without producing any other observable change in the blood.”
— Haycraft JB. On the action of a secretion obtained from the medicinal leech on the coagulation of the blood. Proc R Soc Lond 1884;36:478–487 (p. 487)
“The leech is, perhaps, the only animal known to us which produces a substance that, having entered the body of another animal, opposes itself to one of that animal's most vital chemical processes — the act of coagulation.”
— Haycraft JB, Edinburgh Med J, 1884
External Resources
Influenced Research
Compounds and research areas tracing back to this figure's contributions:
Related Figures
Izolda P. Baskova (Изольда Парфирьевна Баскова)
Russian (Soviet)
Moscow State University biochemist and physiologist who, with G. I. Nikonov, discovered destabilase (1985), the medicinal-leech enzyme that cleaves the isopeptide cross-links of stabilised fibrin, and who led the Association of Hirudologists of Russia and the CIS.
Béchade (Bordeaux leech breeders)
French
Gironde farming family who had solved the feeding problem of leech culture by 1835 and from 1845 ran a leech-breeding and trading business in Bordeaux — the lineage that later became Ricarimpex.
Robert G. Brankamp
American
Cincinnati biochemist whose studies of leech-derived factor Xa inhibitors established the sequence of ghilanten, its heparin-binding domain and its recombinant production in yeast.
François-Joseph-Victor Broussais
1772-1838 · French
French military physician and professor whose physiological medicine doctrine drove the early-nineteenth-century explosion in therapeutic leech use across Paris hospitals and the wider French medical world.